Grip strength test performed date and time

General Details:

Name:
Grip strength test performed date and time
Steward:
NINDS
Definition:
Date (and time, if applicable and known) that grip strength testing was done
Registration Status:
Qualified

Permissible Values:

Value Type:
Date
Unit of Measure:
Ids:
Value Code Name Code Code System Code Description

Designations:

Designation:
Grip strength test performed date and time
Tags:
Designation:
Date Performed
Tags:
Question Text

Designations:

Definition:
Date (and time, if applicable and known) that grip strength testing was done
Tags:

Reference Documents:

ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA; Neals/Cytokinetics Study Team. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(5):430–438.
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA; Neals/Cytokinetics Study Team. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(5):430&#8211;438.<br /><br />ISO 8601 - https://www.iso.org/iso-8601-date-and-time-format.html
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Shefner J, Cudkowicz ME, Maragakis N, Cedarbaum JM, Lee J, Jones D, Watson ML, Shaver K, Chen M, Saikali K, Mao J, Russell AK, Hansen L, Malik F, Wolff AA, for the NEALS/Cytokinetics Study Team. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in Amyotrophic Lateral Sclerosis. (submitted for publication) ISO 8601 - http://www.iso.org/iso/iso_catalogue.htm
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
ISO 8601 - https://www.iso.org/iso-8601-date-and-time-format.html <br /><br />Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.<br /><br />Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.<br /><br />Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.<br /><br />van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.<br /><br />Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.<br /><br />Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.

Identifiers:

Source:
NLM
Id:
ONdz7cBxf_E
Version:
3.1
Source:
NINDS
Id:
C10852
Version:
3
Source:
BRICS Variable Name
Id:
GripStrengthTestPerfDateTime
Version: